SHH De Novo Completed Dosing of First Patient in China in Phase I Clinical Study for ATR inhibitor DN020198
Source: Date:2023-07-04
Shanghai De Novo Pharmatech announcedachievement of important First-in-Human milestone in China in phase I Trialswith the novel investigational ATR inhibitor DN020198. This Phase I study is designedto investigate the safety, tolerability, pharmacokinetics/pharmacodynamics andpreliminary antitumor activity of DN020198 in Chinese patients with advancedsolid tumors (CTR20231411).
沪公网安备 31011502005675号